EU/3/09/713

About

Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2020 on request of the sponsor.

On 29 January 2010, orphan designation (EU/3/09/713) was granted by the European Commission to Immunomedics GmbH, Germany, for veltuzumab for the treatment of chronic lymphocytic leukaemia.

Key facts

Active substance
Veltuzumab
Disease / condition
Treatment of chronic lymphocytic leukaemia
Date of first decision
29/01/2010
Outcome
Withdrawn
EU designation number
EU/3/09/713

Review of designation

Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2020 on request of the sponsor.

Sponsor's contact details

Immunomedics GmbH
Paul-Ehrlich-Str. 22/D1
63322 Rödermark
Germany
Tel. +49 61 51 66 715 66
E-mail: europe@immunomedics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating